<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-17-99
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NATRILIX 1.5 MG S.R TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INDAPAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LES LABORATOIRES SERVIER INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03BA11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NATRILIX SR is a prolonged-release film-coated tablet containing indapamide as active ingredient. Indapamide is a diuretic. Most diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only causes a slight increase in the amount of urine produced.</p><p>&nbsp;</p><p>This medicine is intended to reduce high blood pressure (hypertension) in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take NATRILIX SR - if you are allergic to indapamide or any other sulphonamide or to any of the other ingredients of this medicine (listed in section 6), - if you have severe kidney disease, - if you have severe liver disease or suffer from a condition called hepatic encephalopathy (degenerative disease of the brain), - if you have low potassium levels in your blood. b. Take special care with NATRILIX SR Talk to your doctor, health care provider or pharmacist before taking NATRILIX SR - if you have liver problems, - if you have diabetes, - if you suffer from gout, - if you have any heart rhythm problems or problems with your kidneys, - If you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to a week of taking Natrilix SR. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulfonamide allergy, you can be at higher risk of developing this. - if you have muscle disorders including muscle pain, tenderness, weakness or cramps, - if you need to have a test to check how well your parathyroid gland is working. You should tell your doctor or health care provider if you had photosensitivity reactions. Your doctor or health care provider may give you blood tests to check for low sodium or potassium levels or high calcium levels. If you think any of these situations may apply to you or you have any questions or doubts about taking your medicine, you should consult your doctor, health care provider or pharmacist. Athletes should be aware that this medicine contains an active ingredient, which may give a positive reaction in doping tests. c. Taking other medicines, herbal or dietary supplements and NATRILIX SR Tell your doctor, health care provider or pharmacist if you are taking, have recently taken or might take any other medicines. You should not take NATRILIX SR with lithium (used to treat depression) due to the risk of increased levels of lithium in the blood. Make sure to tell your doctor or health care provider if you are taking any of the following medicines, as special care may be required: - medicines used for heart rhythm problems (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, digitalis, bretylium), - medicines used to treat mental disorders such as depression, anxiety, schizophrenia&hellip; (e.g. tricyclic antidepressants, antipsychotic drugs, neuroleptics (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol)), - bepridil (used to treat angina pectoris, a condition causing chest pain), - cisapride, diphemanil (used to treat gastro-intestinal problems), - antibiotics used to treat bacterial infections (e.g sparfloxacin, moxifloxacin, erythromycin by injection, - vincamine by injection (used to treat symptomatic cognitive disorders in elderly including memory loss), - halofantrine (antiparasitic drug used to treat certain types of malaria), - pentamidine (used to treat certain types of pneumonia), - antihistamines used to treat allergic reactions, such as hay fever (e.g mizolastine, astemizole, terfenadine) (, - non-steroidal anti-inflammatory drugs for pain relief (e.g. ibuprofen) or high doses of acetylsalicylic acid, - angiotensin converting enzyme (ACE) inhibitors (used to treat high blood pressure and heart failure), - amphotericin B by injection (anti-fungal medicines), - oral corticosteroids used to treat various conditions including severe asthma and rheumatoid arthritis, - stimulant laxatives, - baclofen (to treat muscle stiffness occurring in diseases such as multiple sclerosis), - allopurinol (for the treatment of gout), - potassium-sparing diuretics (e.g. amiloride, spironolactone, triamterene), - metformin (to treat diabetes), - iodinated contrast media (used for tests involving X-rays), - calcium tablets or other calcium supplements, - ciclosporin, tacrolimus or other medicines to depress the immune system after organ transplantation, to treat autoimmune diseases, or severe rheumatic or dermatological diseases, - tetracosactide (to treat Crohn&rsquo;s disease). - methadone (used to treat addiction), e. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, health care provider or pharmacist for advice before taking this medicine. This medicine is not recommended during pregnancy. When a pregnancy is planned or confirmed, the switch to an alternative treatment should be initiated as soon as possible. Please tell your doctor or health care provider if you are pregnant or wish to become pregnant. The active ingredient is excreted in milk. Breastfeeding is not recommended if you are taking this medicine. f. Driving and using machines This medicine can cause side effects due to lowering of the blood pressure such as dizziness or tiredness (see section 4). These side effects are more likely to occur after initiation of the treatment and after dose increases. If this occurs, you should refrain from driving and other activities requiring alertness. However, under good control, these side effects are unlikely to occur. g. NATRILIX SR 1.5mg contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor, health care provider or pharmacist has told you. Check with your doctor, health care provider or pharmacist if you are not sure. The recommended dose is one tablet each day, preferably in the morning. The tablets can be taken irrespective of meals. They should be swallowed whole with water. Do not crush or chew them. Treatment for high blood pressure is usually life-long. a. If you take more NATRILIX SR, than you should If you have taken too many tablets, contact your doctor, health care provider or pharmacist immediately. A very large dose of NATRILIX SR could cause nausea, vomiting, low blood pressure, cramps, dizziness, drowsiness, confusion and changes in the amount of urine produced by the kidneys. b. If you forget to take NATRILIX SR If you forget to take a dose of your medicine, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose. c. If you stop taking NATRILIX SR As the treatment for high blood pressure is usually life-long, you should discuss with your doctor or health care provider before stopping this medicinal product. If you have any further questions on the use of this medicine, ask your doctor , health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking the medicinal product and see a doctor immediately, if you experience any of the following side effects that can be serious: - Angioedema and/or urticaria. Angioedema is characterised by swelling of the skin of extremities or face, swelling of the lips or tongue, swelling of the mucous membranes of the throat or airways resulting in shortness of breath or difficulty of swallowing. If this occurs, contact your doctor or health care provider immediately (Very rare) (may affect up to 1 in 10,000 people) - Severe skin reactions including intense skin rash, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome) or other allergic reactions, (Very rare) (may affect up to 1 in 10,000 people) - Life-threatening irregular beat (Not known) - Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell (Very rare) (may affect up to 1 in 10,000 people) - Disease of the brain caused by liver illness (Hepatic encephalopathy) (Not known) - Inflammation of the liver (Hepatitis) (Not known) - Muscle weakness, cramps, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (Not known) In decreasing order of frequency, other side effects can include: Common (may affect up to 1 in 10 people): - Red raised skin rash - Allergic reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions - Low potassium in the blood Uncommon (may affect up to 1 in 100 people): - Vomiting, - Red pinpoints on skin (Purpura) - Low sodium in the blood that may lead to dehydration and low blood pressure, - Impotence (inability to obtain or maintain an erection). Rare (may affect up to 1 in 1000 people): - Feeling of tiredness, headache, pins and needles (paresthesia), vertigo - Gastro-intestinal disorders (such as nausea, constipation), dry mouth - Low chloride in the blood - Low magnesium in the blood Very rare (may affect up to 1 in 10,000 people): - Changes in blood cells, such as thrombocytopenia (decrease in the number of platelets which causes easy bruising and nasal bleeding), leucopenia (decrease of white blood cells which may cause unexplained fever, soreness of the throat or other flu-like symptoms &ndash; if this occurs, contact your doctor or health care provider) and anaemia (decrease in red blood cells) - High level of calcium in blood - Heart rhythm irregularities, low blood pressure - Kidney disease - Abnormal hepatic function Not known (frequency cannot be estimated from the available data): - Fainting - If you suffer from systemic lupus erythematous (a type of collagen disease), this might get worse - Cases of photosensitivity reactions (change in skin appearance) after exposure to the sun or artificial UVA have also been reported - Short sightedness (myopia) - Blurred vision - Visual impairment - Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma) - Changes may occur in your laboratory parameters (blood tests) and your doctor or health care provider may need to give you blood tests to check your condition. The following changes in laboratory parameters may occur: . increase in uric acid, a substance which may cause or worsen gout (painful joint(s) especially in the feet) . increase in blood glucose levels in diabetic patients . increased levels of liver enzymes - Abnormal ECG heart tracing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach&nbsp; of children. Store below 30&deg;C. Store in the original package.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is indapamide. Each tablet contains 1.5 mg of indapamide. The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; tablet &nbsp;core: &nbsp;anhydrous &nbsp;colloidal &nbsp;silica &nbsp;(E551), &nbsp;hypromellose &nbsp;(E464), &nbsp;lactose &nbsp;monohydrate, magnesium stearate (E470B), povidone.</p><p>-&nbsp;&nbsp; film-coating: glycerol (E422), hypromellose (E464), macrogol 6000, magnesium stearate (E470B), titanium dioxide (E171).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is a white, round prolonged-release film-coated tablet.
The tablets are available in blisters of 10, 14, 15, 20, 30, 50, 60, 90 or 100 tablets packed in a cardboard box. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->a.&nbsp; <!--[endif]-->Marketing Authorisation Holder</p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex &ndash; France</p><p>&nbsp;</p><p>Manufacturer</p><p>Les Laboratoires Servier Industrie</p><p>905 route de Saran</p><p>45520 Gidy &ndash; France</p><p>&nbsp;</p><p>Packed by</p><p>AJA Pharmaceutical Industries Company Ltd</p><p>Building No. 6979, Hail Industrial City, Hail 55414</p><p>Saudi Arabia</p><p>Tel.: +966 11 268 7900</p><p>Fax: +966 11 268 7911</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Saudi Arabia</p><p dir="ltr"><strong>Servier Saudi Arabia Scientific Office&nbsp;</strong></p><p dir="ltr"><strong>3533 As Sulaimaniyah - Hitteen Dist.&nbsp;</strong></p><p dir="ltr"><strong>1st floor - Office #101&nbsp;</strong></p><p dir="ltr"><strong>Kingdom of Saudi Arabia</strong></p><p dir="ltr"><strong>Tel.: +966 011 252 2330</strong></p><p><strong>E-mail: regulatory.sa1@servier.com</strong></p><p>&nbsp;</p><p>Gulf Countries</p><p>Les Laboratoires Servier Scientific Office</p><p>P.O. Box 1586, Level 115, Arenco Tower,</p><p>Dubai Media city, Sheikh Zayed Road,</p><p>Dubai, UAE</p><p>Tel: +971 4 3329903</p><p>E-mail: magdy.abdou@ servier.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11.2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ناتريليكس اس ار عبارة عن حبّات ملبسة مديدة التحرير، تحتوي على الإنداباميد كمادة فعّالة.</p><p dir="RTL">إن الإنداباميد مدّر للبول. وإن مدرّات البول تعمل برفع مقدار البول الصادر عن الكليتين. ولكن الإنداباميد</p><p dir="RTL">مختلف عن بقية مدرّات البول بحيث أ نه يرفع البول المدر بمقدار ضئيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء معدّ لتخفيض ضغط الدم المرتفع (ارتفاع الضغط) لدى البالغين.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما الذي یجب أن تعرفھ قبل أن تتناول ناتریلیكس اس ار أ - لا یجوز استعمال ناتریلیكس اس ار في الأوضاع التالیة &bull; ّ إن كان لك حساسیة من الإندابامید، أو من أي سلفونامید آخر، أو من أي مرك ّ ب من مركبات ھذا الدواء،(المذكورة في القسم ٦.( &bull; إن كنت تشكو من مرض كلوي شدید، &bull; إن كنت تشكو من داء في الكبد أو من اعتلال دماغي كبدي ( ّ أي تنكس في الدماغ ) &bull; إن كان مقدار البوتاسیوم منخفض في دمك. ب - علیك بأخذ احتیاطات خاصة مع ناتریلیكس اس ار في الأوضاع التالیة تحدث إلى طبیبك أو مزود الرعایة الصحیة أو الصیدلاني قبل أن تتناول ناتریلیكس اس ار &bull; إن كنت تشكو من داء في الكبد، &bull; إن كنت تشكو من داء السكري، &bull; إن كنت مصابا بالنقرس، ّة، &bull; إن كنت تشكو من اضطرابات في ضربات القلب أو من اضطرابات كلوی &bull; إذا كنت تشكو من تراجع الرؤیة أو من ألم في العینین. قد تكون ھذه أعراض تراكم السوائل في الطبقة الوعائیة للعین (انصباب مشیمي)، أو لارتفاع الضغط في العین، ومن الممكن أن تحدث في غضون ساعات أو أسابیع من تناول فلودكس 5,1 ملغ. وقد تؤدي إلى فقدان البصر إذا تركت دون علاج. إذا كنت مصابا بالحساسیة تجاه البنسلین أو السلفامیدات، فربما تكون أكثر عرضة للإصابة بھ. &bull; إذا كنت تعاني من أي مشاكل عضلیة، ومن ضمنھا الألم، أو المضض، أو الضعف أو التشنجات، ّة لكي تعرف مدى جودة عملھا. &bull; إن كنت سوف تقوم بإ ّ جراء فحص للغدة الدرقی ّ وعلیك بإعلام الطبیب أو مزود الرعایة الصحیة في حال حصل لك تفاعلات تحسس من النور. ّة تمكنھ من مراقبة المقادیر ّ وقد یصف لك الطبیب أو مزود الرعایة الصحیة بعض التحالیل المخبری المنخفضة للصودیوم أو للبوتاسیوم أو المقادیر المرتفعة للكالسیوم في الدم. فإن بدا لك بأن ھذه الاحتیاطات تابعة لوضعك أو إن أردت طرح أسئلة أخرى تابعة لاستعمال ھذا الدواء، علیك ّ بالاسترشاد لدى الطبیب أو مزود الرعایة الصحیة أو الصیدلاني. ّة في فحص تناول ّالة قد تعطي نتائج إیجابی ویحاط الریاضیون علما بأن ھذا الدواء یحتوي على مادة فع ّة. المنشطات الاصطناعی ج - أخذ أدویة أخرى، أو مكملات عشبیة أو غذائیة مع ناتریلیكس اس ار ّ أخبر طبیبك أو مزود الرعایة الصحیة أو الصیدلاني إن كنت تأخذ أو إن كنت قد أخذت مؤخرا أو قد تتناول أي دواء آخر. ولایجوز أخذ ناتریلیكس اس ار مصطحبا مع مادة اللیثیوم ( الأدویة المستعملة في علاج الاكتئاب)،لتفادي ارتفاع مقدار اللیثیوم في الدم. ّ كن حریصا على إعلام الطبیب أو مزود الرعایة الصحیة إن كنت تأخذ أیا من الأدویة التالیة، حیث ینبغي أخذ الاحتیاطات اللازمة : &bull; الأدویة المستعملة في علاج خلل ضربات القلب (مثل كینیدین، ھیدروكینیدین، دیزوبیرامید، أمیودارون، سوتالول، إیبوتیلید، دوفیتیلید، دیجیتالین، بریتیلیوم)، &bull; الأدویة المستعملة في علاج الإضطرابات النفسیة مثل الاكتئاب، أو القلق، أو الفصام... ( مثل مضادات ّ الاكتئاب ثلاثي الحلقات، أو مھدئات الأعصاب، أو مضادات الذھان (مثل أمیسولبرید، ٍسولبیرید، سولتوبرید، تیابرید، ھالوبیریدول، دروبیریدول))، ، ّة)، &bull; ببریدیل bepridil ) لمعالجة الذبحة الصدریة: مرض ینتج عنھ أوجاع صدری ّة)، ّة المعوی &bull; سیزابرید cisapride ، دیفیمانیل diphemanil) المستعملة لمعالجة الاضطرابات المعدی ّة لمعالجة حالات العدوى البكتیریة (مثل: سبارفلوكساسین sparfloxacin ، موكسیفلوكساسین &bull;مضادات حیوی moxifloxacin ،إریثرومایسین erythromycin عن طریق الحقن ) &bull; فنكامین vincamine عن طریق الحقن ( المستعمل لعلاج الاضطرابات الادراكیة المترافقة بأعراض لدى المسنین بما في ذلك فقد الذاكرة)، ّات لعلاج بعض أنواع الملاریا)، &bull; ھالوفانترین halofantrine) مضاد للطفیلی &bull; بنتامیدین pentamidine) لعلاج بعض أنواع ذات الرئة)، &bull; &bull; ّ مضادات الھستامین التي تستعمل لعلاج التفاعلات التحسسیة/ مثل حمى القش (مثل: میزولاستین/ أستیمیزول، تیرفینادین)، &bull; مضادات الإلتھاب غیر الستیرویدیة لتسكین الوجع (مثل ibuprofen ،( أو الجرعات المرتفعة من السالیسیلات، ّطات خمیرة التحویل (ACE) (المستعملة في علاج ارتفاع الضغط الشریاني والقصور القلبي)، &bull; مثب &bull; أمفوتریسین ب B amphotericin عن طریق الحقن ( أدویة مضادة للفطریات ) &bull; الستیرویدات القشریة (corticosteroids (التي تؤخذ عن طریق الفم لمختلف الحالات بما فیھا الربو الشدید أوالتھاب المفاصل الرثیاني، ّھة &bull; ّ المسھلات المنب &bull; باكلوفین baclofen) لعلاج تي بس العضلات الناتج عن التصلب المتعدد)، &bull; ألوبیورینول allopurinol) لعلاج النقرس ) &bull; ّ مدرات البول الكابتة للبوتاسیوم( triamterene, spironolactone, amiloride،( &bull; متفورمین metformine) لعلاج داء السكري)، ّة)، &bull; ّ المواد الملونة بالیود ( المستعملة في فحوصات الأشع ّات الكالسیوم أو كمالیّات الكالسیوم، &bull; حب &bull; سیكلوسبورین ciclosporin ، تاكرولیموس tacrolimus وغیرھا من كابتات المناعة المستعملة في عملیّات ّة الخطیرة، ّة والأمراض الروماتیزمیة والأمراض الجلدی زرع الأعضاء وفي علاج أمراض المناعة الذاتی &bull; تیتراكوزاكتید tetracosactide) لعلاج مرض كرون disease s&rsquo;Crohn( &bull; میتادون (الذي یستعمل في علاج الإدمان). ـھ - الحمل والإرضاع إذا كنت حاملا أو مرضعة، أو كنت تعتقدین بأنك حامل أو كنت تخططین للحمل، فاطلبي نصیحة طبیبك ّ أو مزود الرعایة الصحیة أو الصیدلاني قبل المباشرة بتعاطي أي دواء. لا یوصى باستعمال ھذا الدواء في أثناء الحمل. فإن كان الحمل متوقعا أو مؤكدا، ، وجب اللجوء إلى علاج آخر بأسرع وقت ممكن. تتوق . ّ ِ فعلیك ّ بإعلام الطبیب أو مزو عین الحمل ِ د الرعایة الصحیة إن كنت ِ حاملا أو إن كنت ّ ِ ب الإرضاع إن كنت تتعالجین بھذا ّالة لھذا الدواء تتسرب إلى حلیب الأم، لذا یجب تجن وإن المادة الفع الدواء. و - إلى سائقي السیارات والعاملین على الآلیات قد ینتج عن ھذا الدواء آثار جانبیة ناتجة عن انخفاض الضغط الشریاني، منھا الإحساس بالدوار أو بالتعب ّة في بادئ العلاج أو في حال زیادة (انظر إلى المقطع رقم ٤ .(ومن المرجح أن تظھر تلك الآثار الجانبی ّارات أو القیام بعمل یستدعي الیقظة. لكن بفضل حسن ّب قیادة السی الجرعة. فإن حصل لك ھذا علیك بتجن المراقبة من غیر المرجح أن تحدث تلك الآثار الجانبیة. ز - معلومات ھامة تابعة لبعض ّ مركبات ناتریلیكس اس ار یحتوي ناتریلیكس اس ار على سكر الحلیب وحید الماء. ّ إذا كان طبیبك قد أخبرك أنك مصاب بعدم تحم ّ ل أنواع معینة من السكر، فاتصل بطبیبك أو بمزود الرعایة الصحیة قبل أن تتناول ھذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دوما على تناول ھذا الدواء حسب تعلیمات طبیبك أو مزود الرعایة الصحیة أو الصیدلاني. ویجب ّ تسأل طبیبك أو مزو . أن د الرعایة الصحیة أو الصیدلاني إذا لم تكن متأكدا ُستحسن أخذھا في الصباح. یبلغ مقدار الجرعة الموصى بتناولھا ح بة واحدة فقط في الیوم ، ی ُبتلع الحبة مع قلیل من الماء دون سحقھا أو مضغھا. یمكن أخذ الحبة بغض النظر عن موعد وجبة الطعام. ت وبشكل عام، فإن علاج ارتفاع الضغط الشریاني یستمر مدى الحیاة. أ - في حال أخذت ناتریلیكس اس ار أكثر من اللازم ّصال د الرعایة الصحیة أو الصیدلاني. فإن ّات متعددة، علیك بالات ّ فورا بالطبیب أو مزو إن طرأ وتناولت حب ّ أخذ جرعة مرتفعة من ناتریلیكس اس ار قد یؤدي إلى حدوث غثیان، قيء، انخفاض الضغط الشریاني، ُعاس، ارتفاع مقدار البول الناتج عن الكلیتین. ّة، دوخة، ن تشنجات عضلی ب - في حال سھوت عن أخذ ناتریلیكس اس ار إن سھوت عن تناول جرعة من دوائك، فتناول الجرعة التالیة في وقتھا الاعتیادي. لا تتناول جرعة مضاعفة للتعویض عن جرعة منسیة. ج - في حال التوقف عن أخذ ناتریلیكس اس ار ّ وبحیث أن علاج ارتفاع الضغط علاج یستمر مدى الحیاة، علیك باستشارة الطبیب أو مزود الرعایة الصحیة قبل التو قف عن ھذا العلاج. ّ وإن أردت طرح أي سؤال تابع لاستعمال ھذا الدواء، فاسأل الطبیب أو مزود الرعایة الصحیة أو لدى الصیدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما ھي الحال مع كافة الأدویة، فقد تنتج عن ھذا الدواء ، آثار جانبیة، رغم أن الأشخاص. توقف عن تناول ھذا المستحضر الدوائي وراجع طبیبا على الفور، إذا أصبت بأي من الآثار الجانبیة التالیة والتي قد تكون خطیرة: - وذمة وعائیة و/أو شرى. تتصف الوذمة الوعائیة بتورم في جلد الأطراف أو الوجھ، تورم الشفتین أو اللسان، تورم الأغشیة المخاطیة في الحلق أو الممرات الھوائیة مما یؤدي إلى ضیق النفس أو صعوبة البلع. إذا حدث ھذا، فاتصل بطبیبك أو مزود الرعایة الصحیة على الفور ( نادرة جدا) (قد تصیب حتى واحد بالعشرة آلاف شخص ) - تفاعلات جلدیة شدیدة تتضمن طفح جلدي شدید ، احمرار الجلد في جمیع أنحاء الجسم، حكة شدیدة، تشكل ن ّ فاطات، تقشر وتورم الجلد، التھاب الأغشیة المخاطیة ( متلازمة ستیفنس جونسون ) أو تفاعلات تحسسیة أخرى ( نادرة جدا) (قد تصیب حتى واحد بالعشرة آلاف شخص ) - ضربات قلب غیر منتظمة مھددة للحیاة ( ّ غیر معروفة المعد ل ) - بنكریاس ملتھب مما قد یسبب ألما شدیدا في البطن والظھر یرافقھ شعور بالاعیاء الشدید ( نادرة جدا) (قد تصیب حتى واحد بالعشرة آلاف شخص ) - مرض في الدماغ ناتج عن إصابة كبدیة ( اعتلال دماغي كبدي) ( ّ غیر معروف المعدل ) - ضعف، تشنجات، مضض العضلات أو ألمھا، وبشكل خاص، إذا شعرت في نفس الوقت بتوعك أو ارتفاع في درجة الحرارة، فقد یكون ذلك - التھاب الكبد ( ّ غیر معروف المعدل ) ّ بسبب التدرك العضلي غیر الطبیعي (معدّل حدوثھا غیر معروف). بمعدل حدوث متناقص، یمكن للآثار الجانبیة الأخرى أن تشمل : &bull; شائعة ( قد تصیب حتى واحد من كل عشرة أشخاص): - طفح جلدي، اثار حمراء. ّة أو لدى &bull; تفاعلات تحسسیة، جلدیة بشكل رئیسي، ّ لدى الأشخاص المعرضین للتفاعلات الحساسی المصابین بالربو. &bull; ّ انخفاض معدل البوتاسیوم في الدم. &bull; غیر - شائعة ( قد تصیب حتى واحد من مائة شخص): - قيء - بقع حمراء صغیرة على الجلد ( فرفریة ) - انخفاض معدل الصودیوم في الدم والذي قد یؤدي إلى جفاف وھبوط ضغط الدم، ّة (عدم القدرة على تحقیق الانتصاب أو المحافظة علیھ). - عن &bull; نادرة ( قد تصیب حتى واحد من ألف شخص:) - الإحساس بالتعب ( الوھن) ّ ، أو صداع، أو تنمل بالأطراف ( المذل)، أو دوخة؛ َویة ( غثیان أو إمساك)، تجفف في الفم؛ - ِ اضطرابات مع ِ دیة مع - ّ انخفاض معدل الكلورید في الدم؛ - انخفاض ّ معدل المغنیزیوم في الدم. &bull; نادرة جدا ( قد تصیب حتى واحد من عشرة آلاف شخص): تغیرات في خلایا الدم مثل قل ( ینتج عنھا سھولة حدوث الكدمات والنزف من الأنف)، ّ - ة الصفیحات أو قلة الكریات البیض ( َّ تنتج عنھا سخونة غیر مبررة، أو ألم في الحنجرة، اعراض مثل الانفلونزا أي قل )؛ ّ - ّ فإن حدث لك ھذا اتصل بطبیبك أو مزود الرعایة الصحیة)، فقر دم ( ة الكریات الحمر - ارتفاع معدل الكالسیوم في الدم. - اضطرابات في ضربات القلب، انخفاض ضغط الدم. - مرض الكلیة . - اضطراب في عمل الكبد. &bull; غیر معروفة (لا یمكن تقدیر معدل الحدوث استنادا إلى البیانات المتوفرة): - إغماء - ُ إن كنت تشكو من ذئبة حمامیة جھازیة ( وھو عبارة عن داء كولاجیني ) فیمكن لھذا الداء أن یشتد. ّة الشمس أو - حدوث أعراض تحسس من النور ( ینتج عنھا تغیر في مظھر الجلد ) ّ بعد التعرض لأشع ّة. ّة فوق البنفسجی ّة اصطناعی - لأشع - حسر البصر - تشوش الرؤیة - اعتلالات بصریة - تراجع الرؤیة أو ألم في العینین بسبب ارتفاع الضغط ( علامات محتملة لتراكم السوائل في الطبقة الوعائیة من العین ( انصباب مشیمي) أو زرق حادّ مغلق الزاویة). - قد تحدث تغیرات في مقاییس الدم ( اختبارات الدم) ّ ، مما یحض طبیبك أو مزود الرعایة الصحیة ّرات التي قد تحصل ھي : لطلب إجراء بعض التحالیل المخبریّة لدمك. وإن التغی o ارتفاع مقدار حمض البولة، قد ینتج عنھ حدوث أو تدھور أعراض النقرس ( ألم في المفاصل وخاصة على مستوى القدمین ) o ارتفاع مقدار السكر في الدم لدى المصابین بداء السكري، o ارتفاع مقدار الإنزیمات الكبدیة - تبدلات غیر طبیعیة في مخطط القلب الكھربائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تدع ھذا الدواء في متناول أیدي الأطفال أو في حقل نظرھم. ُحفظ ھذا الدواء في مكان لا تتجاوز حرارتھ ۳۳ درجة مئویة في علبتھ الاصلیة. ی لا تستعمل ھذا الدواء بعد تاریخ الفعالیّة المبیّن على العلبة وعلى الغلاف. تاریخ انتھاء الفعالیّة ھو آخر یوم من الشھر. لا تتخلص من الأدویة في میاه المجاري العامة أو مع قمامة المنزل. اسأل الصیدلاني عن طریقة التخلص من الأدویة التي لم تعد بحاجة إلیھا. ھذه الإجراءات ستساعد على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي إنداباميد. تحتوي كل حبة على ١٫٥ ملغ من إنداباميد. -</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في نواة الحبّة: السيليكا الغروانيّة اللامائيّة - (E551) ، هيبروملوز (E464) ، سكر الحليب (لاكتوز) وحيد الماء، ستيارات المغنيزيوم (E470B) ، بوفيدون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مادة التلبيس: غليسيرول - (E422) ، هيبروملوز (E464) ، ماكروغول ٦٣٣٣ ، ستيارات المغنيزيوم (E470B) ، ثاني أكسيد التيتانيوم (E171) .</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">هذا الدواء عبارة عن حبّات بيضاء اللون مستديرة الشكل ملبّسة مديدة التحرير.</p><p dir="RTL" style="text-align:right">تتوفر الحبات في شرائط نفطية تحتوي على 10، 14، 15، 20، 30، 50، 60، 90، أو 100 حبّة معبأة في علبة كرتونية. .</p><p dir="RTL" style="text-align:right">قد لا يتم تسويق كافة أحجام العبوات.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong><u>صاحب رخصة التسويق</u></strong></p><p>مختبرات سرفييه</p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex &ndash; France</p><p><strong>المصنّع</strong></p><p>مختبرات سرفييه للتصنيع</p><p>Les Laboratoires Servier Industrie</p><p>905, route de Saran</p><p>45520 Gidy</p><p>France</p><p>&nbsp;</p><p dir="RTL">تمت التعبئة بواسطة شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">مبنى رقم 6979 ، المدينة الصناعية بحائل، حائل 55414</p><p>المملكة العربية السعودية</p><p dir="RTL">هاتف: 7900 268 11 966+</p><p dir="RTL">فاكس: 7911 268 11 966+</p><p>&nbsp;</p><p>&nbsp;</p><p>للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي لصاحب رخصة التسويق.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:585px"><tbody><tr><td style="vertical-align:top; width:271px"><p dir="RTL">المملكة العربیة السعودیة المكتب العلمي لشركة سیرفیر العربیة السعودیة 3533 الحوي ، حي حطین، مكتب 101 المملكة العربیة السعودیة ھاتف: ۹٦٦۱۱2522330+ regulatory.sa1@servier.com : الالكتروني البرید</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top; width:311px"><p dir="RTL"><strong>بلدان الخليج</strong></p><p dir="RTL">مكتب العلمي لمختبرات سرفييه</p><p dir="RTL">ص.ب. 1586 ، الطابق 115 ، برج أرينكو، مدينة دبي</p><p dir="RTL">الإعلامية</p><p dir="RTL">طريق الشيخ زايد، دبي، الإمارات العربية المتحدة</p><p dir="RTL">هاتف: 3329903 4 971+</p><p dir="RTL">البريد الإلكتروني:</p><p dir="RTL">&nbsp;magdy.abdou@servier.com</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة الأخيرة على هذه النشرة في 11/ 2021.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Natrilix SR, prolonged-release film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prolonged-release film-coated tablet contains 1.5 mg indapamide.
Excipient with known effect: 124.5 mg lactose monohydrate
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet.
White, round, film-coated tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natrilix SR is indicated in essential hypertension in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology One tablet per 24 hours, preferably in the morning, to be swallowed whole with water and not chewed. At higher doses the antihypertensive action of indapamide is not enhanced but the saluretic effect is increased. Special populations Renal impairment (see sections 4.3 and 4.4): In severe renal failure (creatinine clearance below 30 ml/min), treatment is contraindicated. Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired. Hepatic impairment (see sections 4.3 and 4.4): In severe hepatic impairment, treatment is contraindicated. Elderly (see section 4.4): In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with Natrilix SR when renal function is normal or only minimally impaired. Paediatric population: The safety and efficacy of Natrilix SR in children and adolescents have not been established. No data are available. Method of administration Oral use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance, to other sulfonamides or to any of the excipients listed in section 6.1.
-	Severe renal failure.
-	Hepatic encephalopathy or severe impairment of liver function.
-	Hypokalaemia.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special warnings When liver function is impaired, thiazide-related diuretics may cause, particularly in case of electrolyte imbalance, hepatic encephalopathy which can progress to hepatic coma. Administration of the diuretic must be stopped immediately if this occurs. Photosensitivity: Cases of photosensitivity reactions have been reported with thiazides and thiazide-related diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA. Excipients: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine. Special precautions for use - Water and electrolyte balance: &bull; Plasma sodium: This must be measured before starting treatment, then at regular intervals subsequently. The fall in plasma sodium may be asymptomatic initially and regular monitoring is therefore essential, and should be even more frequent in the elderly and cirrhotic patients (see sections 4.8 and 4.9). Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences. Hyponatraemia with hypovolaemia may be responsible of dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight. &bull; Plasma potassium: Potassium depletion with hypokalaemia is the major risk of thiazide and related diuretics. Hypokalaemia may cause muscle disorders. Cases of Rhabdomyolysis have been reported, mainly in the context of severe hypokalaemia. The risk of onset of hypokalaemia (&lt; 3.4 mmol/l) must be prevented in certain high risk populations, i.e. the elderly, malnourished and/or polymedicated, cirrhotic patients with oedema and ascites, coronary artery disease and cardiac failure patients. In this situation, hypokalaemia increases the cardiac toxicity of digitalis preparations and the risks of arrhythmias. Individuals with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as well as bradycardia, is then a predisposing factor to the onset of severe arrhythmias, in particular, potentially fatal torsades de pointes. More frequent monitoring of plasma potassium is required in all the situations indicated above. The first measurement of plasma potassium should be obtained during the first week following the start of treatment. Detection of hypokalaemia requires its correction. Hypokalaemia found in association with low serum magnesium concentration can be refractory to treatment unless serum magnesium is corrected. Plasma magnesium: Thiazides and related diuretics including indapamide have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5 and 4.8).. &bull; Plasma calcium: Thiazide and related diuretics may decrease urinary calcium excretion and cause a slight and transitory rise in plasma calcium. Frank hypercalcaemia may be due to previously unrecognised hyperparathyroidism. Treatment should be withdrawn before the investigation of parathyroid function. - Blood glucose: Monitoring of blood glucose is important in diabetics, in particular in the presence of hypokalaemia. - Uric acid: Tendency to gout attacks may be increased in hyperuricaemic patients. - Renal function and diuretics: Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired (plasma creatinine below levels of the order of 25 mg/l, i.e. 220 &micro;mol/l in an adult). In the elderly, this plasma creatinine must be adjusted in relation to age, weight and gender. Hypovolaemia, secondary to the loss of water and sodium induced by the diuretic at the start of treatment causes a reduction in glomerular filtration. This may lead to an increase in blood urea and plasma creatinine. This transitory functional renal insufficiency is of no consequence in individuals with normal renal function but may worsen preexisting renal insufficiency. - Athletes: The attention of athletes is drawn to the fact that this medicinal product contains a drug substance, which may give a positive reaction in doping tests. - Choroidal effusion, acute myopia and secondary angle-closure glaucoma: Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Combinations that are not recommended: Lithium: Increased plasma lithium with signs of overdosage, as with a salt-free diet (decreased urinary lithium excretion). However, if the use of diuretics is necessary, careful monitoring of plasma lithium and dose adjustment are required. Combinations requiring precautions for use: Torsades de pointes-inducing drugs such as but not limited to: - class Ia antiarrhythmic agents (e.g quinidine, hydroquinidine, disopyramide), - class III antiarrhythmic agents (e.g amiodarone, sotalol, dofetilide, ibutilide, bretylium), - some antipsychotics : phenothiazines (e.g chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (e.g amisulpride, sulpiride, sultopride, tiapride) butyrophenones (e.g droperidol, haloperidol), other antipsychotic (e.g pimozide), other substances: bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV, methadone, astemizole, terfenadine). Increased risk of ventricular arrhythmias, particularly torsades de pointes (hypokalaemia is a risk factor). Monitor for hypokalaemia and correct, if required, before introducing this combination. Clinical, plasma electrolytes and ECG monitoring. Use substances which do not have the disadvantage of causing torsades de pointes in the presence of hypokalaemia. N.S.A.I.Ds. (systemic route) including COX-2 selective inhibitors, high dose acetyl salicylic acid (&ge; 3 g/day): Possible reduction in the antihypertensive effect of indapamide. Risk of acute renal failure in dehydrated patients (decreased glomerular filtration). Hydrate the patient; monitor renal function at the start of treatment. Angiotensin converting enzyme (A.C.E.) inhibitors: Risk of sudden hypotension and/or acute renal failure when treatment with an A.C.E. inhibitor is initiated in the presence of preexisting sodium depletion (particularly in patients with renal artery stenosis).</p><p>In hypertension, when prior diuretic treatment may have caused sodium depletion, it is necessary: - either to stop the diuretic 3 days before starting treatment with the A.C.E. inhibitor, and restart a hypokalaemic diuretic if necessary; - or give low initial doses of the A.C.E. inhibitor and increase the dose gradually. In congestive heart failure, start with a very low dose of A.C.E. inhibitor, possibly after a reduction in the dose of the concomitant hypokalaemic diuretic. In all cases, monitor renal function (plasma creatinine) during the first weeks of treatment with an A.C.E. inhibitor. Other compounds causing hypokalaemia: amphotericin B (IV), gluco- and mineralo-corticoids (systemic route), tetracosactide, stimulant laxatives: Increased risk of hypokalaemia (additive effect). Monitoring of plasma potassium and correction if required. Must be particularly borne in mind in case of concomitant digitalis treatment. Use non-stimulant laxatives. Baclofen: Increased antihypertensive effect. Hydrate the patient; monitor renal function at the start of treatment. Digitalis preparations: Hypokalaemia and/or hypomagnesaemia predispose to the toxic effects of digitalis. Monitoring of plasma potassium, magnesium and ECG and, if necessary, adjust the treatment. Combinations requiring special care: Allopurinol: Concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol. Combinations to be taken into consideration: Potassium-sparing diuretics (amiloride, spironolactone, triamterene): Whilst rational combinations are useful in some patients, hypokalaemia or hyperkalaemia (particularly in patients with renal failure or diabetes) may still occur. Plasma potassium and ECG should be monitored and, if necessary, treatment reviewed. Metformin: Increased risk of metformin induced lactic acidosis due to the possibility of functional renal failure associated with diuretics and more particularly with loop diuretics. Do not use metformin when plasma creatinine exceeds 15 mg/l (135 &micro;mol/l) in men and 12 mg/l (110 &micro;mol/l) in women. Iodinated contrast media: In the presence of dehydration caused by diuretics, increased risk of acute renal failure, in particular when large doses of iodinated contrast media are used. Rehydration before administration of the iodinated compound. Imipramine-like antidepressants, neuroleptics: Antihypertensive effect and increased risk of orthostatic hypotension (additive effect). Calcium (salts): Risk of hypercalcaemia resulting from decreased urinary elimination of calcium. Ciclosporin, tacrolimus: Risk of increased plasma creatinine without any change in circulating ciclosporin levels, even in the absence of water/sodium depletion. Corticosteroids, tetracosactide (systemic route): Decreased antihypertensive effect (water/sodium retention due to corticosteroids).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of indapamide in pregnant women. Prolonged exposure to thiazide during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a foeto-placental ischaemia and growth retardation. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Indapamide during pregnancy. Breast-feeding There is insufficient information on the excretion of indapamide/metabolites in human milk. Hypersensitivity to sulphonamide-derived medicines and hypokalaemia might occur.A risk to the newborns/infants cannot be excluded. Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with decrease or even suppression of milk lactation. Indapamide is not recommended during breast-feeding. Fertility Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indapamide does not affect vigilance but different reactions in relation with the decrease in blood pressure may occur in individual cases, especially at the start of the treatment or when another antihypertensive agent is added. As a result the ability to drive vehicles or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The most commonly reported adverse reactions are hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes.</p><p>During clinical trials, hypokalaemia (plasma potassium &lt;3.4 mmol/l) was seen in 10 % of patients and</p><p>&lt; 3.2 mmol/l in 4 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.23 mmol/l.</p><p>The majority of adverse reactions concerning clinical or laboratory parameters are dose-dependent.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>The following undesirable effects have been observed with indapamide during treatment ranked under the following frequency:</p><p>Very common (&sup3; 1/10); common (&sup3; 1/100 to &lt;1/10); uncommon (&sup3; 1/1,000 to &lt; 1/100); rare (&sup3;1/10,000 to &lt;1/1,000); very rare (&sup3;1/100,000 to &lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA</strong><strong> </strong><strong>System</strong><strong> </strong><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Undesirable</strong><strong> </strong><strong>Effects</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p><p><strong>Blood</strong><strong> and the lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p><strong>Metabolism</strong><strong> </strong><strong>and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Potassium depletion with hypokalaemia, particularly serious in certain high risk populations (see section 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia (see section 4.4)</p></td><td style="vertical-align:top"><p>Not know</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p><p><strong>Nervous</strong><strong> System disorders</strong></p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paresthesia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p><strong>Eye</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p><strong>Myopia</strong></p></td><td style="vertical-align:top"><p><strong>Not</strong><strong> known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Choroidal effusion</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blurred</strong><strong> </strong><strong>vision</strong></p></td><td style="vertical-align:top"><p><strong>Not</strong><strong> known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Visual</strong><strong> </strong><strong>impairment</strong></p></td><td style="vertical-align:top"><p><strong>Not</strong><strong> known</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Cardiac</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>Arrhythmia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Torsade de pointes (potentially fatal) (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p><p><strong>Gastrointestinal</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p><strong>Hepatobiliary</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>Abnormal hepatic function</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Possibility of onset of hepatic encephalopathy in case of hepatic insufficiency (see sections 4.3 and 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Skin</strong><strong> and Subcutaneous Tissue Disorder</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Maculopapular rashes</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermic necrolysis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson Syndrome</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Possible worsening of pre-existing acute disseminated lupus erythematosus</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal</strong><strong> </strong><strong>and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>Renal failure</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Blood glucose increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Elevated liver enzyme levels</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><em>To report any side effect(s):</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp; <strong><em>Saudi</em></strong><strong><em> </em></strong><strong><em>Arabia:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-National Pharmacovigilance Center (NPC)Laboratories</p><p>- Fax: +966-11-205-7662</p><p>-&nbsp; SFDA call Center 19999</p><p>-&nbsp; Toll free phone: 8002490000</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='width:465pt;
 height:91.1pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".58pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='margin-top:.6pt;margin-right:252.25pt;
    margin-bottom:0in;margin-left:11.7pt;margin-bottom:.0001pt;text-align:center;
    text-indent:-6.35pt;mso-list:l1 level1 lfo1;tab-stops:11.75pt'><![if !supportLists]><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi'>-<span style='letter-spacing:-.1pt'> </span><span
    style='letter-spacing:-.05pt'>National Pharmacovigilance</span> <span
    style='letter-spacing:-.05pt'>Center</span> <span style='letter-spacing:
    -.05pt'>(NPC)</span></span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
    0in;margin-left:40.7pt;margin-bottom:.0001pt;line-height:12.6pt;mso-line-height-rule:
    exactly'><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi'>-<span style='letter-spacing:-.2pt'> </span>Fax:<span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>+966-11-205-7662</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-left:46.95pt;text-indent:-6.25pt;
    line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
    tab-stops:47.0pt'><![if !supportLists]><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>SFDA </span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi'>call<span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.05pt'>Center</span> <span style='letter-spacing:
    -.05pt'>19999</span></span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-left:46.95pt;text-indent:-6.25pt;
    line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
    tab-stops:47.0pt'><![if !supportLists]><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi'>Toll<span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.05pt'>free</span><span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>phone:</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>8002490000</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
    0in;margin-left:46.95pt;margin-bottom:.0001pt;text-indent:-6.25pt;
    line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
    tab-stops:47.0pt'><![if !supportLists]><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>E-mail:</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:.05pt'> </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;color:windowtext;letter-spacing:-.05pt'>npc.drug@sfda.gov.sa</span></a><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-left:46.95pt;text-indent:-6.25pt;
    line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
    tab-stops:47.0pt'><![if !supportLists]><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-family:"Times New Roman",serif;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
    mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>Website:</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:.05pt'> </span><a
    href="http://www.sfda.gov.sa/npc"><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;color:windowtext;letter-spacing:-.05pt'>www.sfda.gov.sa/npc</span></a><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong><em>Other</em></strong><strong><em> GCC states:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Please contact the relevant competent authority</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t202"
 style='width:465pt;height:15.25pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".58pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.7pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.3pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi'>-<span style='letter-spacing:-.2pt'> </span>Please
    <span style='letter-spacing:-.05pt'>contact</span><span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.05pt'>the</span> <span
    style='letter-spacing:-.05pt'>relevant</span><span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.05pt'>competent</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>authority.</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><p><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:465pt;
 height:15.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>Indapamide has been found free of toxicity at up to 40 mg, <em>i.e</em>. 27 times the therapeutic dose.</p><p>Signs of acute poisoning take the form above all of water/electrolyte disturbances (hyponatraemia, hypokalaemia). Clinically, possibility of nausea, vomiting, hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria possibly to the point of anuria (by hypovolaemia).</p><p>&nbsp;</p><p>Management</p><p>Initial measures involve the rapid elimination of the ingested substance(s) by gastric wash-out and/or administration of activated charcoal, followed by restoration of water/electrolyte balance to normal in a specialised centre.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Sulfonamides, plain, ATC code: &nbsp;C 03 BA 11 <u>Mechanism of action</u></p><p>Indapamide is a sulphonamide derivative with an indole ring, pharmacologically related to thiazide</p><p>diuretics, which acts by inhibiting the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Phase II and III studies using monotherapy have demonstrated an antihypertensive effect lasting 24 hours. This was present at doses where the diuretic effect was of mild intensity.</p><p>&nbsp;</p><p>The antihypertensive activity of indapamide is related to an improvement in arterial compliance and a reduction in arteriolar and total peripheral resistance.</p><p>Indapamide reduces left ventricular hypertrophy.</p><p>Thiazide and related diuretics have a plateau therapeutic effect beyond a certain dose, while adverse effects continue to increase. The dose should not be increased if treatment is ineffective.</p><p>&nbsp;</p><p>It has also been shown, in the short-, mid- and long-term in hypertensive patients, that indapamide:</p><p><strong>.&nbsp;&nbsp; &nbsp;</strong>does not interfere with lipid metabolism: triglycerides, LDL-cholesterol and HDL-cholesterol;</p><p><strong>.&nbsp;&nbsp; &nbsp;</strong>does not interfere with carbohydrate metabolism, even in diabetic hypertensive patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indapamide 1.5 mg is supplied in a prolonged release dosage based on a matrix system in which the drug substance is dispersed within a support which allows sustained release of indapamide.</p><p>&nbsp;</p><p><u>Absorption:</u></p><p>The fraction of indapamide released is rapidly and totally absorbed via the gastrointestinal digestive tract.</p><p>Eating slightly increases the rapidity of absorption but has no influence on the amount of the drug absorbed.</p><p>Peak serum level following a single dose occurs about 12 hours after ingestion, repeated administration reduces the variation in serum levels between 2 doses. Intra-individual variability exists.</p><p>&nbsp;</p><p><u>Distribution:</u></p><p>Binding of indapamide to plasma proteins is 79%.</p><p>The plasma elimination half-life is 14 to 24 hours (mean 18 hours). Steady state is achieved after 7 days.</p><p>Repeated administration does not lead to accumulation.</p><p>&nbsp;</p><p><u>Metabolism:</u></p><p>Elimination is essentially urinary (70% of the dose) and faecal (22%) in the form of inactive metabolites.</p><p>&nbsp;</p><p><u>High risk individuals:</u></p><p>Pharmacokinetic parameters are unchanged in renal failure patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indapamide has been tested negative concerning mutagenic and carcinogenic properties.</p><p>The highest doses administered orally to different animal species (40 to 8000 times the therapeutic dose) have shown an exacerbation of the diuretic properties of indapamide. The major symptoms of poisoning during acute toxicity studies with indapamide administered intravenously or intraperitoneally were related to the pharmacological action of indapamide, <em>i.e</em>. bradypnoea and peripheral vasodilation.</p><p>Reproductive toxicity studies have not shown embryotoxicity and teratogenicity. Fertility was not impaired either in male or in female rats.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet:</em></p><p>Silica, colloidal anhydrous</p><p>Hypromellose</p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>Povidone</p><p>&nbsp;</p><p><em>Film-coating: </em></p><p>Glycerol</p><p>Hypromellose</p><p>Macrogol 6000</p><p>Magnesium stearate</p><p>Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10, 14, 15, 20, 30, 50, 60, 90, 100 tablets in heat-sealed aluminium/ Polyamide-aluminium polyvinyl chloride blister packed in a carton Box.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier 50, rue Carnot
92284 Suresnes cedex – France

Packed by
AJA Pharmaceutical Industries Company Ltd 
Building No. 6979, Hail Industrial City, Hail 55414
 Saudi Arabia
Tel.: +966 11 268 7900
Fax: +966 11 268 7911


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 11.2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>